Please assess the completion status of the following clinical trial:

Trial Title: Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Participant is healthy, as determined by medical history and physical examination.~* Participant is 2 years to \< 5 years of age at the time of vaccination.~* At least one year from primary vaccination with a monovalent meningococcal C conjugate vaccine has elapsed.~* Parent/Guardian has signed an Ethics Committee-approved informed consent form. A culturally appropriate translation will be used for non-English speaking participants where required.~Exclusion Criteria :~* Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic, etc.)~* Known or suspected impairment of immunologic function~* Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5ºC at the time of inclusion~* History of documented invasive meningococcal disease~* Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrolment~* Antibiotic therapy within the 72 hours prior to vaccination or 72 hours prior to drawing any blood sample~* Received any vaccine in the 28-day period prior to enrolment, or scheduled to receive any vaccine during enrolment in the trial~* Received a meningococcal C conjugate vaccine within one year prior to enrolment~* Suspected or known hypersensitivity to any of the vaccine components~* Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures~* Enrolled in another clinical trial~* Any condition, which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 4 Years
- Healthy Volunteers: t

Study Arms:
- Menactra® Vaccine Group (Type: EXPERIMENTAL): Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
- Hiberix® Vaccine Group (Type: ACTIVE_COMPARATOR): Participants receiving Haemophilus Influenzae Type b (Hib) vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).